9 completed, 4 terminated, 1 recruiting. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 9, Terminated 4, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Natalizumab: new trials by email Literature Review of Natalizumab trials Research Report on Natalizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 21 | 2022-04-26 | 2025-11-25 |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 585 | 2018-11-27 | 2024-06-12 |
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis natalizumab, Placebo - Secondary Progressive Multiple Sclerosis | Phase 3 | Terminated | Biogen | 889 | 2011-09-13 | 2017-09-11 |
| Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Natalizumab (BG00002), Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Biogen | 106 | 2010-11-01 | 2014-10-21 |
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 84 | 2010-03-01 | 2014-09-03 |
| Natalizumab (Tysabri) Re-Initiation of Dosing Natalizumab - Relapsing-Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 1094 | 2006-03-01 | 2016-07-15 |
| Natalizumab Re-Initiation of Dosing BG00002 (natalizumab) - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 404 | 2006-03-01 | 2017-03-21 |
| A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 462 | 2004-03-01 | 2016-06-16 |
| Open-Label Natalizumab Safety Extension Study Natalizumab - Multiple Sclerosis | Phase 3 | Completed | Biogen | 1615 | 2003-12-01 | 2009-06-22 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 2002-03-01 | 2016-06-16 | |
| Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis Natalizumab, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 1200 | 2002-01-01 | 2009-06-18 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 905 | 2001-12-01 | 2016-06-16 |
| Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Natalizumab, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 900 | 2001-11-01 | 2017-01-09 |
Multiple Sclerosis, Relapsing-Remitting (8) · Multiple Sclerosis (6) · Crohn Disease (3) · Multiple Sclerosis, Chronic Progressive (2) · Colitis (1) · Inflammatory Bowel Diseases (1) · Neoplasm Metastasis (1)
Biogen (13) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (10) · Canada (7) · France (6) · Belgium (5) · Germany (5) · Italy (5) · Czechia (4) · Israel (4) · Netherlands (4) · Spain (4) · United Kingdom (4) · Australia (3) · Finland (3) · Poland (3) · Sweden (3)
Michael Panzara, MD, MPH (3) · Chris Polman, MD (1) · Eve Versage (1) · George E. Georges, MD (1) · Jeffrey A. Cohen, MD (1) · Paolo A. Muraro, MD, PhD (1) · Paul O'Connor, MD (1) · Richard A Rudick, MD (1)
PMID 16267322, PMID 37173129, PMID 16510744, PMID 16510745, PMID 20737510, PMID 20737514, PMID 22521274, PMID 24898925, PMID 28078634, PMID 28104251, PMID 29545067, PMID 34376508, PMID 35483387, PMID 35720980, PMID 37652990, PMID 38469809, PMID 39046635, PMID 39393045
2018 (1), UM1AI109565 (1)